Johns Hopkins University at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Johns Hopkins University takes part in 3 sessions at ESMO 2026 in Madrid. Its sessions cover lung cancer, from early detection to metastatic disease, and advanced biliary tract cancer. It presents work tracing blood-based genomic and protein markers of early lung cancer to sources inside and outside the tumour, and a randomised trial of paclitaxel with or without tovecimig.

OrganizationESMO 2026 Attendance
jhu.edu
University & institute
Private research university in Baltimore, Maryland, with a school of medicine and a comprehensive cancer centre.
Abstract
Sat Oct 24
10:15–10:25
459O - A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer
Proffered paper 2: Gastrointestinal tumours, upper digestive
Gastrointestinal cancers
Abstract
Sun Oct 25
10:35–10:45
Invited Discussant 2613O and 2614O
Proffered paper 1: NSCLC, metastatic
Lung & thoracic cancers
Abstract
Sun Oct 25
14:45–14:55

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Johns Hopkins University

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction